Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Frederic Colombel

Showing results (321-330 of 377) with videos related to

Pageof 38
Sort By:
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The American Journal of Gastroenterology|January 26, 2024
Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter ExperienceJeffrey A Berinstein, Taylor Karl, Anish Patel, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Gastroenterology|February 12, 2020
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's DiseaseWilliam J Sandborn, Brian G Feagan, Edward V Loftus, et al.
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2021
Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination TherapyRoman Kosoy, Seunghee Kim-Schulze, Adeeb Rahman, et al.
Gut|May 1, 2019
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free miceJoana Torres, Jianzhong Hu, Akihiro Seki, et al.
Archives of Iranian Medicine|February 4, 2024
Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle EastHasan Vosoghinia, Bahar Saberzadeh-Ardestani, Amir Anushiravani, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Pageof 38

Showing results (321-330 of 377) with videos related to

Sort By:
Pageof 38
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The American Journal of Gastroenterology|January 26, 2024
Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter ExperienceJeffrey A Berinstein, Taylor Karl, Anish Patel, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Gastroenterology|February 12, 2020
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's DiseaseWilliam J Sandborn, Brian G Feagan, Edward V Loftus, et al.
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2021
Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination TherapyRoman Kosoy, Seunghee Kim-Schulze, Adeeb Rahman, et al.
Gut|May 1, 2019
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free miceJoana Torres, Jianzhong Hu, Akihiro Seki, et al.
Archives of Iranian Medicine|February 4, 2024
Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle EastHasan Vosoghinia, Bahar Saberzadeh-Ardestani, Amir Anushiravani, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Pageof 38